Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.
Journal: International journal of hematology
Published: April 14, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
Journal: Journal of hematology & oncology
Published: December 30, 2025
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.
Journal: Blood advances
Published: August 27, 2025
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.
Journal: Blood advances
Published: August 27, 2025
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Journal: Transplantation and cellular therapy
Published: May 17, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Journal: Bone marrow transplantation
Published: August 18, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 29, 2023
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Journal: Cancer discovery
Published: August 30, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2022
Last Updated: 09/26/2026